197 related articles for article (PubMed ID: 38257978)
1. Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin-Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing
Gatti M; Bonazzetti C; Pascale R; Giannella M; Viale P; Pea F
Microorganisms; 2024 Jan; 12(1):. PubMed ID: 38257978
[TBL] [Abstract][Full Text] [Related]
2. Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing
Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136770
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections.
Berrino PM; Gatti M; Rinaldi M; Brunocilla E; Viale P; Pea F
Antibiotics (Basel); 2023 Aug; 12(9):. PubMed ID: 37760685
[TBL] [Abstract][Full Text] [Related]
4. Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections.
Gatti M; Rinaldi M; Laici C; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998801
[TBL] [Abstract][Full Text] [Related]
5. Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration.
Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2023 Oct; 12(10):. PubMed ID: 37887225
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant
Gatti M; Giannella M; Rinaldi M; Gaibani P; Viale P; Pea F
Antibiotics (Basel); 2022 Dec; 11(12):. PubMed ID: 36551398
[TBL] [Abstract][Full Text] [Related]
7. Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections?
Gatti M; Rinaldi M; Bonazzetti C; Gaibani P; Giannella M; Viale P; Pea F
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0096923. PubMed ID: 37843260
[TBL] [Abstract][Full Text] [Related]
8. A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis.
Gatti M; Tedeschi S; Trapani F; Ramirez S; Mancini R; Giannella M; Viale P; Pea F
Antibiotics (Basel); 2022 Aug; 11(8):. PubMed ID: 36009906
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections.
Gatti M; Campoli C; Latrofa ME; Ramirez S; Sasso T; Mancini R; Caramelli F; Viale P; Pea F
Pediatr Infect Dis J; 2023 Nov; 42(11):975-982. PubMed ID: 37523585
[TBL] [Abstract][Full Text] [Related]
10. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia.
Gatti M; Pascale R; Cojutti PG; Rinaldi M; Ambretti S; Conti M; Tedeschi S; Giannella M; Viale P; Pea F
Int J Antimicrob Agents; 2023 Jan; 61(1):106699. PubMed ID: 36464151
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
Cojutti PG; Morandin E; Baraldo M; Pea F
Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW;
Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029
[TBL] [Abstract][Full Text] [Related]
14. Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem.
Sanz Codina M; Gatti M; Troisi C; Fornaro G; Pasquini Z; Trapani F; Zanoni A; Caramelli F; Viale P; Pea F
Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015211
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF).
Gatti M; Rinaldi M; Tonetti T; Gaibani P; Siniscalchi A; Viale P; Pea F
Int J Antimicrob Agents; 2023 Aug; 62(2):106852. PubMed ID: 37192727
[TBL] [Abstract][Full Text] [Related]
16. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol.
Gatti M; Bartoletti M; Cojutti PG; Gaibani P; Conti M; Giannella M; Viale P; Pea F
J Glob Antimicrob Resist; 2021 Dec; 27():294-298. PubMed ID: 34710630
[TBL] [Abstract][Full Text] [Related]
17. Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever.
Maarbjerg SF; Thorsted A; Friberg LE; Nielsen EI; Wang M; Schrøder H; Albertsen BK
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1585. PubMed ID: 34796702
[TBL] [Abstract][Full Text] [Related]
18. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.
Maillard A; Delory T; Bernier J; Villa A; Chaibi K; Escaut L; Contejean A; Bercot B; Robert J; El Alaoui F; Tankovic J; Poupet H; Cuzon G; Lafaurie M; Surgers L; Joseph A; Paccoud O; Molina JM; Bleibtreu A;
Int J Antimicrob Agents; 2023 Jul; 62(1):106809. PubMed ID: 37028731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
